Plasma Protein Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The plasma protein therapeutics market size is expected to grow from USD 32.17 billion in 2025 to USD 33.88 billion in 2026 and is forecast to reach USD 43.86 billion by 2031 at 5.3% CAGR over 2026-2031. This report Segments the Industry by Product (Immunoglobulin, Albumin, and More), by Application (Immunology & Neurology Disorders, Hematology & Coagulation Disorders, and More), by End-User (Hospitals and Clinics, Homecare and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Plasma Protein Therapeutics Market Trends and Insights

Rising Adoption of Home-Based Sub-Cutaneous Immunoglobulin Therapy

FDA approval of an expanded XEMBIFY label in July 2024 enables treatment-naïve patients to initiate subcutaneous therapy without prior intravenous dosing, thereby reducing clinic visits and expanding the addressable population. Phase 4 data confirm biweekly dosing maintains total Ig levels, enhancing adherence. Home infusion reduces healthcare resource utilization by 69% compared to IV administration, resulting in payer savings and higher manufacturer margins. Direct-to-patient logistics support new revenue streams, while improved quality of life drives patient preference toward self-administration. Manufacturers are responding with nurse-support apps and wearable pump programs that further reduce treatment burden.

Expansion of Plasma Collection Centers

CSL Plasma’s roll-out of the Rika system across nearly half its U.S. network trims donation sessions to 35 minutes, a 30-50% throughput gain that directly lifts plasma volume. Simultaneously, the FDA is drafting risk-based donor guidelines that replace rigid time-based deferrals with individual assessments, expected to enlarge the eligible donor pool. These moves relieve a chronic supply bottleneck hampering the plasma protein therapeutics market. Advanced centers also deploy comfort-enhancing lounges and digital booking, improving donor retention. Collectively, the infrastructure expansion sets higher capital barriers that smaller firms struggle to match, reinforcing incumbent advantages.

Strict Regulations for the Handling of Plasma Protein Products

The FDA mandates donor-specific collection volumes, calculated by sex, weight, and hematocrit, which adds workflow complexity and a software validation burden. Emerging economies face additional hurdles, including limited cold-chain infrastructure and slower licensure processes, which can delay product launches. The 2025 FDA guidance agenda lists five fresh documents on blood components, signaling further regulatory churn. Large incumbents leverage in-house regulatory affairs teams to navigate shifting rules, consolidating market power.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Incidence of Autoimmune and Neurological Diseases
• Increasing Approval of Extended Half-Life Coagulation Factors in Japan & South Korea
• High Cost & Limited Reimbursement

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Immunoglobulins generated 42.10% of 2025 revenue, demonstrating the single largest plasma protein therapeutics market share in a portfolio spanning primary immunodeficiencies and neurological disorders. The segment’s sustained growth is fueled by subcutaneous formulations that migrate therapy from hospital to home, further enlarging demand. Innovations such as Grifols’ XEMBIFY, which posted 15.8% annual sales growth, exemplify the resilience of this category. Simultaneously, the coagulation factor arena is shifting toward gene-based cures; approval momentum for CSL Behring’s HEMGENIX underlines the gradual substitution of replacement therapy with potentially one-time interventions.

Alpha-1 antitrypsin products represent the fastest-expanding niche, advancing at a forecast 5.92% CAGR through 2031 as early-diagnosis programs uncover latent AATD patients. Gene-editing pipelines led by Prime Medicine promise disease-modifying potential, attracting institutional investors. C1 esterase inhibitors preserve a specialized yet essential role for hereditary angioedema management, with steady uptake driven by improved diagnostic awareness. Hyperimmune globulins, meanwhile, are carving new territory by targeting emerging infectious diseases, offering manufacturers a counter-cyclical revenue hedge.

Complete Report Scope:

• By Product Type
  • Immunoglobulins
    • Intravenous Ig
    • Sub-cutaneous Ig
    • Hyperimmune Globulins (Anti-D, Hep B, Varicella, RSV, others)
  • Albumin Coagulation Factors
  • Coagulation Factors
    • Factor VIII
    • Factor IX
    • von Willebrand Factor
    • Fibrinogen Concentrate
  • Alpha-1 Antitrypsin
  • C1 Esterase Inhibitor
  • Other Plasma-Derived Proteins
• By Application
  • Immunology & Neurology Disorders
    • Primary Immunodeficiency (PID)
    • Secondary Immune Deficiency
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • Myasthenia Gravis
  • Hematology & Coagulation Disorders
    • Hemophilia A
    • Hemophilia B
    • von Willebrand Disease
  • Respiratory Disorders
  • Critical Care & Trauma
  • Others
• By End-User
  • Hospitals and Clinics
  • Specialty Plasma Centers
  • Homecare
  • Research & Academic Institutes
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia- Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Africa
    • South Africa
    • Nigeria
    • Egypt
    • Rest of Africa

Geography Analysis

North America commanded 41.10% of 2025 global revenue, anchored by more than 1,000 FDA-licensed plasma collection facilities and broad insurance coverage. The FDA’s clearance of the Rika device, which halves collection time, directly addresses supply adequacy. Pending risk-based donor regulations could further expand the eligible donor base and cement regional leadership. Manufacturers leverage strong reimbursement ecosystems, although value-based contracts are emerging for high-cost gene therapies, reshaping long-term pricing models.

Asia-Pacific is forecast to grow at 7.61% CAGR, the quickest pace globally. China’s blood products market aided by Terumo’s USD 15 million localization investment earmarked for 2025. Indonesia’s forthcoming 600,000-liter fractionation plant exemplifies public-private collaboration aimed at reducing import dependence. Japan and South Korea grant accelerated approvals for EHL coagulation factors, positioning the sub-region as an innovation testbed.

Europe maintains strategic importance but grapples with a projected 4-8 million-liter plasma gap by 2025, prompting calls for 2 million additional donors. The Proposed SoHO Regulation underscores donor safety and quality but may impose extra compliance costs. Nevertheless, recent positive reimbursement decisions for HEMGENIX illustrate payer readiness to fund transformative therapies. Middle East & Africa and South America, while smaller, are benefitting from gradual diagnostic expansion and donor-education campaigns, setting the stage for steady uptake

List of Companies Covered in this Report:

• CSL Behring
• Takeda Pharmaceuticals
• Grifols
• Octapharma
• Kedrion Biopharma
• China Biologics Products
• GC Pharma (Green Cross Corp.)
• Biotest
• Bio Products Laboratory Ltd (BPL)
• ADMA Biologics
• Kamada Ltd.
• LFB S.A.
• Sanquin Plasma Products B.V.
• Hualan Biological
• Bharat Serums & Vaccines Ltd.
• Emergent Bio Solutions
• Intas Pharmaceuticals Ltd. (Accord)
• Prothya Biosolutions
• Shenzhen Kangtai Biological Products
• ProMetic BioTherapeutics Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support